Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial

• Published in: Pediatric nephrology (Berlin, West) Vol. 27; no. 3; pp. 389 - 396
• Main Authors: Baudouin, Véronique, Alberti, Corinne, Lapeyraque, Anne-Laure, Bensman, Albert, André, Jean-Luc, Broux, Françoise, Cailliez, Mathilde, Decramer, Stéphane, Niaudet, Patrick, Deschênes, Georges, Jacqz-Aigrain, Evelyne, Loirat, Chantal
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.03.2012; Springer; Springer Nature B.V
• Subjects: Adolescent; Analysis; Area Under Curve; Bayes Theorem; Care and treatment; Child; Child, Preschool; Clinical trials; Corticosteroids; Female; Humans; Immunosuppressive agents; Immunosuppressive Agents - therapeutic use; Kidney diseases; Male; Medicine; Medicine & Public Health; Mycophenolic Acid - adverse effects; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - pharmacokinetics; Mycophenolic Acid - therapeutic use; Nephrology; Nephrotic syndrome; Nephrotic Syndrome - drug therapy; Original Article; Pediatrics; Pharmacokinetics; Prednisone - therapeutic use; Prospective Studies; Steroids; Urology; France; Paris France; Mycophenolic acid pharmacokinetics; Steroid-dependent nephrotic syndrome; Bayesian trial; Mycophenolate mofetil; Idiopathic nephrotic syndrome

Mycophenolate mofetil (MMF) has emerged as a new therapeutic option in steroid-dependent nephrotic syndrome (SDNS). We conducted a phase II Bayesian trial of MMF in children with SDNS. Phase II trials, usually single-arm studies, investigate the effect of new treatments. Standard Fleming’s procedure...